Preliminary experience with a 'sub-50' combined oral contraceptive, containing 35 micrograms ethinyl oestradiol and 1 mg norethisterone ('NeoCon').
The present trend in oral contraception is clearly in favour of the 'sub-50' pills, taking into consideration the recent publications on the association between cardiovascular affections and pill intake. 'NeoCon', a combination pill containing 1 mg norethisterone and 35 micrograms ethinyl oestradiol, has been investigated in the United States, Mexico, Germany, Belgium and the United Kingdom. From all these studies, it could be concluded that it is an effective and well-tolerated oral contraceptive. From the present series, totalling 104 patients with 1232 cycles, first clinical impressions confirm the evaluations of other investigators: no pregnancies, only mild cycle disturbances disappearing after a few adaptation cycles, few side-effects and excellent tolerance. Due to the low potency and the low contents of its components, it is suggested that 'NeoCon' is appropriate for all women in general and for the younger women in particular.
D000293:Adolescent; D000328:Adult; D001835:Body Weight / Q000187:drug effects; D003276:Contraceptives, Oral / Q000494:pharmacology; D003277:Contraceptives, Oral, Combined / Q000494:pharmacology; D004997:Ethinyl Estradiol; D005260:Female; D006801:Humans; D007989:Libido / Q000187:drug effects; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D009640:Norethindrone
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D004997:Ethinyl Estradiol; D009640:Norethindrone